NCT06302270Recruiting
CFTR Modulators in Pregnancy and Postpartum
Monitoring of Women and Children Exposed to the Combination of Elexacaftor-tezacaftor-ivacaftor During Bregnancy and Through Mother's Own Milk.
Source: ClinicalTrials.gov · Last updated 8 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 4 Mar 2024
- Start date
- 15 Mar 2024
- Primary completion date
- 31 Jan 2034
- Lead sponsor
- Region Stockholm
- Diseases
- Cystic fibrosis
- NCT number
- NCT06302270
What you commit to
- Study type: Observational
- Planned participants: 75
- From 15 Mar 2024 to the primary completion date, 31 Jan 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- Woman with cystic fibrosis who is pregnant and treated with Kaftrio. Newborn infant to the above mentioned woman
Age in the registry: - to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stockholm CF center Coordinator of this site? Confirm its status | Stockholm | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.